Founded in 2000, the Tübingen-based biopharmaceutical company CureVac is a technology leader in the development of drugs based on messenger RNA (mRNA). The company uses the body's own principle, in which mRNA is used as an information carrier for the construction of proteins that the body can then produce itself. The RNA people pursue the major goal of bringing drugs and prophylactic vaccines based on mRNA onto the market, thereby helping patients and preventing infectious diseases.
RNActive® cancer immunotherapy
RNActive® cancer immunotherapies stimulate the patient's immune system to fight the tumor with a specific immune response. CureVac's compounds consist of different mRNA molecules encoding different tumor antigens (proteins or peptides that are expressed on tumor cells but show little or no expression on healthy tissues).
CureVac develops RNActive agents for the treatment of various types of cancer in collaboration with Boehringer Ingelheim and Eli Lilly.
RNActive® Prophylactic vaccines
RNActive® vaccines represent a new generation of promising and cost-effective mRNA-based vaccines for the prophylaxis of infectious diseases. A rabies vaccine based on a new formulation is being tested on healthy volunteers. CureVac is also working with the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines against other infectious diseases.
CureVac's mRNA-based technology RNArt® targets the body's own production of therapeutic proteins and antibodies. In rare diseases, for example, missing proteins such as enzymes can be expressed in the liver. The expression of therapeutic antibodies for the therapy of various diseases and passive immunotherapy of infections is also possible.
In-house GMP production
CureVac has been operating its own GMP production facilities since 2006, enabling the company to produce all (m)RNA active ingredients in a short time. The facilities have been successfully tested several times by government agencies and have received manufacturing approvals for clinical trial material. This approval was last granted in autumn 2019 for GMP III. The company is currently building another production plant in Tübingen on an industrial scale.
CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Jean Stéphenne, former deputy Chairman of the…
The company rejects current rumors of an acquisition
TÜBINGEN, Germany/ BOSTON – March 11, 2020 – CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced…
CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force
- White House today invited representatives of pharmaceutical and biotech companies leading the COVID-19 response effort
- CureVac currently selecting best vaccine…